EP1558215A1 - Sterile gelling agents - Google Patents

Sterile gelling agents

Info

Publication number
EP1558215A1
EP1558215A1 EP03748442A EP03748442A EP1558215A1 EP 1558215 A1 EP1558215 A1 EP 1558215A1 EP 03748442 A EP03748442 A EP 03748442A EP 03748442 A EP03748442 A EP 03748442A EP 1558215 A1 EP1558215 A1 EP 1558215A1
Authority
EP
European Patent Office
Prior art keywords
gelling agent
sterile
organic solvent
solvent
water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03748442A
Other languages
German (de)
French (fr)
Other versions
EP1558215A4 (en
Inventor
Prabhakar Harshal Wockhardt Limited BHAGWATWAR
Balkrishna Mahesh Wockhardt Limited PAITHANKAR
Pradeep Wockhardt Limited SHARMA
Ramesh Varada Wockhardt Limited BAPAT
Alibhai Ismail Wockhardt Limited MATHAKIYA
Shahajirao Chandrashekhar Kadam
Subhash Bhushan Wockhardt Limited YEOLA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bapat Varada Ramesh
Bhagwatwar Prabhakar Harshal
KADAM CHANDRSHAKHAR SHIVAJIRAO
Mathakiya Ismail Alibhai
Paithankar Mahesh Balkrishna
Sharma Pradeep
Yeola Bhushan Subhash
Wockhardt Ltd
Original Assignee
Yeola Bhushan S
Wockhardt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeola Bhushan S, Wockhardt Ltd filed Critical Yeola Bhushan S
Publication of EP1558215A1 publication Critical patent/EP1558215A1/en
Publication of EP1558215A4 publication Critical patent/EP1558215A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/04—Oxygen-containing compounds
    • C08K5/10—Esters; Ether-esters
    • C08K5/101—Esters; Ether-esters of monocarboxylic acids
    • C08K5/103—Esters; Ether-esters of monocarboxylic acids with polyalcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Definitions

  • Forms of sterile compositions include sterilization by moist heat (autoclaving), sterilization by dry heat, ethylene oxide sterilization (gaseous sterilization), exposure to ultraviolet rays or to gamma irradiation or sterilization by aseptic processing. These and other methods of sterilization are described in detail in Pharmaceutical Dosage Forms: Parenteral Medications (Eds. Avis, Lachman and Lieberman, Volumes 1-3).
  • sterile controlled release products for parenteral administration such as the microencapsulated products, in-situ forming implants and the in-situ microcarrier forming gelled polymeric dispersions.
  • sterile processing of the in-situ microcarrier forming gelled polymeric dispersions poses the greatest challenge to the formulation scientist because of the complex nature of the delivery composition.
  • These gelled polymeric dispersions are comprised of dispersions of organic solvent solutions of biocompatible polymers in a continuous oleaginous phase gelled and stabilized by emulsifiers chosen from sorbitan monostearate or monopalmitate.
  • the organic solvents are preferably water-soluble though water-immiscible solvents can also be used.
  • the gelling agents of this invention as commercially available are not free from foreign particulate material and contain significant quantities of impurities which add color to the final product making it unacceptable for parenteral use. Further, the use of water for the processing of these gelling agents is not feasible because the gelling agents would degrade during autoclaving for example resulting in a loss of gelling capability. Also, presence of moisture in any of the materials, specially the gelling agent would result in the loss of physical stability of the gelled dispersions. A process to manufacture sterile in-situ microcarrier forming gelled polymeric dispersion compositions would be a tremendous improvement in the current state-of-the- art in the development of commercial products using these compositions.
  • a novel method for the manufacture of sterile gelling agent for use in a suitable composition or delivery system for therapeutic administration involves the use of aseptic processing alone or gamma-irradiation alone or a combination of aseptic processing and gamma irradiation to achieve a product of the desired attributes including sterility, freedom from foreign particulates, syringeability, particle formation upon coming in contact with aqueous media, potency of active, and physical stability.
  • a in-situ microcarrier forming gelled polymeric dispersion composition prepared using the gelling agents treated as above are subjected to gamma irradiation to prepare a sterile product useful for human administration without any significant loss in potency or behavior of the gelled dispersion composition in physical stability, syringeabihty or particle formation upon coming in contact with aqueous media.
  • Another embodiment of the invention describes the administration of this sterile composition to an animal species.
  • the gelling agents of the invention viz. sorbitan monostearate or sorbitan monopalmitate are soluble in a variety of organic solvents including volatile organic solvents such as methylene chloride, ethyl acetate, benzene, petroleum ether, carbon tetrachloride, methanol, acetonitrile, acetone, ethanol, tetrahydrofuran and other volatile solvents, at elevated temperatures.
  • volatile organic solvents such as methylene chloride, ethyl acetate, benzene, petroleum ether, carbon tetrachloride, methanol, acetonitrile, acetone, ethanol, tetrahydrofuran and other volatile solvents
  • Non-volatile organic solvents in which the gelling agents are soluble include NN'-dimethylacetamide (DMA), dimethylsulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), triacetin, triethyl citrate, benzyl alcohol, propylene carbonate, decylmethylsulfoxide, dimethylformamide (DMF), glycofural, benzoyl benzoate, alkyl esters of aromatic acids, polyethylene glycols (PEG), propylene glycol and the like, also at elevated temperatures.
  • DMA NN'-dimethylacetamide
  • DMSO dimethylsulfoxide
  • NMP N-methyl-2-pyrrolidone
  • triacetin triethyl citrate
  • benzyl alcohol propylene carbonate
  • decylmethylsulfoxide dimethylformamide (DMF)
  • glycofural glycofural
  • benzoyl benzoate alkyl esters of aromatic acids
  • the solvents for the invention should be biocompatible and not pose toxicity issues. Such solvents may be completely water-miscible, partially water-miscible or completely water-immiscible.
  • Water-im niscible organic solvents such as dichloromethane, chloroform, ether, benzene, hexane and the like though otherwise used in the preparation of pharmaceutical compositions are generally toxic and require exotic methods such as lyophilization and the like for removal. Also, there are very strict guidelines for the levels of such residual solvents allowable in pharmaceutical compositions, especially so for parenteral administration. Water-miscible organic solvents are preferred.
  • water-miscible organic solvents are chosen from DMA, DMSO, NMP, triacetin, triethyl citrate, benzyl alcohol, propylene carbonate, decylmethylsulfoxide, DMF, glycofural, benzoyl benzoate, alkyl esters of aromatic acids, PEG, propylene glycol, isopropanol, methanol, acetonitrile, acetone, ethanol, tetrahydrofuran and the like.
  • a specially preferred volatile water-miscible solvent is ethanol because of its proven antiseptic properties, its complete water-miscibility, its volatile nature, its biocompatibility and low toxicity potential, its solvating capability for the gelling agents of the invention at elevated temperatures and its known use in the pharmaceutical industry for parenteral administration of solution dosage forms.
  • Preferred non-volatile water-miscible organic solvents include DMA, DMSO, DMF, NMP, PEG among others.
  • the sterile bulk gelling agent is prepared by dissolution in volatile water-miscible organic solvents specifically chosen from ethanol, methanol, acetonitrile, acetone, ethanol, tetrahydrofuran at a temperature above ambient, filtered through a sterilizing grade filter membrane at the elevated temperature and dried under vacuum at the elevated temperature.
  • volatile water-miscible organic solvents specifically chosen from ethanol, methanol, acetonitrile, acetone, ethanol, tetrahydrofuran
  • the solution of the gelling agent which has been filtered through a sterilizing grade filter membrane is cooled to room temperature or lower to cause gelation of the solvent and the same solvent is added to the gel to cause precipitation of the gelling agent.
  • This suspension is then filtered through a further sterilizing grade filter membrane and the wet mass which is substantially free from the organic solvent is then dried under vacuum at an elevated temperature.
  • This procedure has the advantage of removal of a large percentage of the organic solvent from the gelled bulk which would otherwise be lost under vacuum.
  • This solvent can then further be used in processing of a separate lot of the gelling agent.
  • substantially free indicates that a large percentage of the organic solvent is removed when compared with the situation where all of the solvent is bound to the gelling agent in the form of a gel.
  • the solution of the gelling agent which has been filtered through sterilizing grade filter membranes at elevated temperatures is then added to a non-solvent to cause precipitation of the gelling agent.
  • the non-solvent can be an organic solvent or can be water.
  • the precipitated gelling agent is then treated further as in the earlier embodiment described above with the same advantages.
  • the water-miscible organic solvent is nonvolatile chosen from DMA, DMSO, NMP, triacetin, triethyl citrate, benzyl alcohol, decylmethylsulfoxide, DMF, glycofural, PEG, propylene glycol and the like.
  • the gelling agent is subjected to drying to remove water.
  • the residual organic solvent should be chosen advantageously to be the same as the one to be used in the final gelled polymeric dispersion.
  • the sterile dried bulk gelling agent is subjected to sterilization by gamma irradiation. Surprisingly, the gelling agents are not degraded by this procedure.
  • Other materials in the gelled polymeric dispersion can be processed by other techniques as described above and generally known in the art of preparation of sterile dosage forms.
  • the concentration of the gelling agent in the water-miscible solvent can be from 5 %w/w to 80 %w/w, preferably from about 10 %w/w to 70 %w/w and even more preferably from about 20 %w/w to 60 %w/w.
  • the concentration of the gelling agent in the final solution will be dependent on the solvent chosen, the gelling agent solvent interactions, the processing temperature and of course the solubility of the gelling agent in the solvent. Of particular importance is the concentration of the gelling agent in the solvent, which allows filtration through a sterilizing grade membrane filter. The higher the concentration of the gelling agent in the solution the greater the yields and smaller the amounts of the expensive solvents that are used.
  • the ratio of the solvent to the non-solvent may be adjusted so that complete precipitation occurs to ensure maximum yields.
  • the temperature of preparation of the solution and also the processing will of course depend on the solvent to be used with a temperature below the boiling point of the solvent being preferred.
  • a clear solution can be prepared at a temperature of 35-40 °C and higher at concentrations as high as 50 %w/w, which can be filtered through a sterilizing grade 0.22 ⁇ m filter at the same temperature.
  • a solvent such as DMA a solution with the same concentration needs to be processed at a higher temperature because of the viscosity imparted by the gelling agent.
  • the gelling agents of the invention are known to gel the solvents of the invention at high concentrations.
  • Each gelling agent-solvent system will have a different temperature range at which the gelation occurs which will also affect the processability of the solution.
  • the sterilizing grade filter can be any membrane, which has the capability to remove foreign particulates and also microorganisms to ensure sterility. Such filters usually have a pore size of 0.22 ⁇ m. Any membrane filter is acceptable for the practice of this invention as long as it can filter the solution and is compatible with the solvents of the invention. Such membranes include those made from nylon 66, cellulose acetate, cellulose nitrate, polytetrafluoroethylene (PTFE), silver membrane, gold membrane, polysulfone, polycarbonate and other known in the art and supplied by various manufacturers.
  • the sterilizing grade filter could be preceded by a cleaning filter such as a 0.45 ⁇ m, 5 ⁇ m or 8 ⁇ m filter which can take up much of the burden from the sterilization filter. The choice of filters is within the scope of a person skilled in the art of development of pharmaceutical injectable dosage forms.
  • Any mode of filtration is acceptable as long as a sterile product is produced.
  • Such methods include, vacuum filtration, filtration under positive pressure using compressed air or nitrogen and the like.
  • cartridge filters or filter candles and the like are well within the scope of this description.
  • the drying of the sterile gelling agent bulk obtained after the above described processes can be conducted by any means known in the art including for example tray drying in an oven with or without the application of vacuum and with or without heating, lyophilization, simple vacuum drying and other methods known to a person skilled in the art of processing pharmaceutical dosage forms. Where heating is required it is preferable to heat at a temperature above the boiling point of the solvent to be evaporated to ensure complete removal of the organic solvent.
  • sterile solvents, polymers, oil and bioactive agents can be as per known procedures in the art such as aseptic filtration of the solvents and oil, gamma irradiation of the polymer or aseptic filtration of the polymer solution in a volatile organic solvent followed by evaporation of the solvent and the like and are well known to persons skilled in the art of manufacture of parenteral controlled release dosage forms.
  • the bioactive agents which can be incorporated into the sterile in-situ microcarrier fo ⁇ riing gelled polymeric dispersion compositions can be chosen from peptide drugs, protein drugs, desensitizing agents, antigens, vaccines, anti-infectives, antibiotics, antimicrobials, antineoplastics, antitumor, antiallergenics, steroidal anti- inflammatory agents, analgesics, decongestants, miotics, anticholinergics, sympathomimetics, sedatives, hypnotics, antipsychotics,.psychic energizers, tranquilizers, androgenic steroids, estrogens, progestational agents, humoral agents, prostaglandins, analgesics, antispasmodics, antimalarials, antihistamines, cardioactive agents, non- steroidal anti-inflammatory agents, antiparkinsonian agents, antihypertensive agents, beta-adrenergic blocking agents, nutritional agents, antivirals, DNA fragment
  • drugs or biologically active agents that can be released in an aqueous environment can be utilized in the described delivery system.
  • various forms of the drugs or biologically active agents may be used. These include, without limitation, forms such as uncharged molecules, molecular complexes, salts, ethers, esters, amides, and other chemically modified forms of the biologically active agent which are biologically activated when injected into a body.
  • the sterile bioactive agent may also be added to the oil phase as a suspension to enhance the loading of the bioactive agent in the delivery composition. Whatever the final composition that is arrived at the process allows a sterile composition to be prepared.
  • parenterally as used herein is intended to include routes such as intramuscular, intravenous, subcutaneous, subdermal, intralesional, intratumoral, intracavitary, peritumoral, intraarticular, vaginal, intraperitoneal, intraabdominal, intrathecal, intraorgan and the like or on open wounds, fractures, ulcers, cancerous lesions and the like and is not to be construed as limiting on the scope of the invention.
  • the composition can be used for the immediate or controlled release or both of bioactive agents or bioinactive agents wherever the use of a sterile composition is called for.
  • Examples 1-5 describe different methods for preparation of sterile sorbitan monostearate. The same methods can be applied to the preparation of other sterile gelling agents including sorbitan monopalmitate.
  • Sorbitan monostearate (Sanyo, Japan) was subjected to sterilization by dry heat at a temperature of 180 °C for 2 hours. A dark brown colored mass was obtained. The material thus obtained though it would pass the test for sterility renders the final product unacceptable for pharmaceutical use because of the dark brown color it imparts.
  • Example 1 Preparation of sterile sorbitan monostearate by direct evaporation of the solvent from a solution in a volatile organic solvent
  • Sorbitan monostearate (Sanyo, Japan) was dissolved in ethanol (50 %w/v) by heating upto 60 - 65 °C in a water bath to form a clear solution.
  • the hot solution was filtered through a 0.2 ⁇ m nylon 66 (Pall German) sterilizing grade membrane filter under vacuum using a specially fabricated jacketed stainless steel filtration assembly, which was also maintained, at the elevated temperature.
  • the filtrate was dried in a vacuum oven at 40 °C and 760 mm vacuum for 48 hours. The dried material was crushed and stored in a sterile container free from moisture.
  • Example 2 Preparation of sterile sorbitan monostearate by dissolving in a hot volatile water- miscible solvent and precipitating by mixing with the same solvent which is cold
  • Sorbitan monostearate (Sanyo, Japan) was dissolved in ethanol (50 %w/v) by heating upto 60 - 65 °C in a water bath to form a clear solution.
  • the hot solution was filtered through a 0.2 ⁇ m nylon 66 (Pall German) sterilizing grade membrane filter under vacuum using a specially fabricated jacketed stainless steel filtration assembly, which was also maintained, at the elevated temperature.
  • the filtered solution was kept at 37 °C for 60 minutes and was then slowly added into cold, sterile, particulate free ethanol at 2 - 8 °C.
  • the sorbitan monostearate precipitated as a fine powder at the bottom of the beaker.
  • the precipitated sorbitan monostearate was collected and dried.
  • Example 3 Preparation of sterile sorbitan monostearate by dissolving in a volatile water- miscible organic solvent and precipitating from a non-solvent Sorbitan monostearate (Sanyo, Japan) was dissolved in ethanol (50 %w/v) by heating upto 60 — 65 °C in a water bath to form a clear solution.
  • the hot solution was filtered through a 0.2 ⁇ m nylon 66 (Pall Gelman) sterilizing grade membrane filter under vacuum using a specially fabricated jacketed stainless steel filtration assembly that was also maintained at the elevated temperature.
  • the sorbitan monostearate was precipitated by drop-wise addition of the filtered ethanolic solution into sterile water for injection. The supernatant was decanted off and the precipitated sorbitan monostearate was collected on a filter paper and dried under vacuum at an elevated temperature. The dried material was crushed and stored in a sterile container free from moisture.
  • Example 4 Preparation of sterile sorbitan monostearate by dissolving in a non-volatile water- miscible solvent and precipitating from a non-solvent
  • Sorbitan monostearate (Sanyo, Japan) was dissolved in DMA (Fluka) by heating upto 60 - 65 °C in a water bath to form a clear solution. This solution was slowly added into sterile water for injection to cause precipitation of sorbitan monostearate, which was collected and dried.
  • Sorbitan monostearate prepared in Example 1 was exposed to gamma irradiation at a dose of 25 KGy using a 60 Cobalt source at a contract irradiation laboratory. A dose of 25 KGy is accepted internationally to be sufficient to ensure sterility (British Pharmacopoeia). There was no change in appearance of the gelling agent.
  • sterile sorbitan monostearate can be prepared by these techniques without any change in properties.
  • the same techniques may be used to prepare sterile sorbitan monopalmitate.
  • the further examples describe the use of the sterile sorbitan monostearate in the preparation of the gelled polymeric dispersions.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention is directed to sterile gelling agents, which retain their physico-chemical properties so that they can be used in drug delivery systems. Also described are the processes for obtaining a sterile gelling agent(s).

Description

STERILE GELLING AGENTS.
FIELD OF THE INVENTION
This invention is directed towards a sterile gelling agent and a process for the manufacture of the gelling agent. The sterile, gelling agent may further be incorporated into delivery systems preferably drug delivery systems.
BACKGROUND OF THE INVENTION
Conventional liquid formulations have been used in the past for the parenteral administration of bioactive agents for the treatment of a variety of disease conditions in human beings and animals. Such formulations include simple aqueous or non-aqueous solutions or suspensions, lyophilized powders for reconstitution for administration via routes such as intravenous, intraarterial, subcutaneous, intramuscular and the like; solid implants for subdermal administration; microencapsulated products for intramuscular administration and the like. More recently, research has focused on the development of controlled release compositions which form the delivery systems inside the body after administration. Such compositions include the ATRIGEL system described by Dunn et al. (4,938,763), the ReGel system developed by Rathi et al. (PCT Application WO 00/18821) and others. Even more recently, delivery compositions which form microcarriers inside the body have been developed to overcome the problems associated with the delivery systems described above. Such problems include prolonged processing times, use of costly equipments, use of toxic and often carcinogenic organic solvents and subsequent problems associated with their removal from the composition and the like. These and other problems are overcome by in-situ microcarrier forming delivery compositions as described by Bhagwatwar et al. (US 20030049320 Al, AU 0222505 A5 and WO 02/49573 A3). All of these compositions are required to be sterile, endotoxin and foreign particulate free to reduce the probability of infections to the animal because of contamination by microorganisms. The term "Foreign particulate free" is meant to indicate the absence of any particulate matter, which is not supposed to be there in the composition and excludes drug particles, controlled release microparticulates and the like. Conventional methods for the manufacture of sterile compositions include sterilization by moist heat (autoclaving), sterilization by dry heat, ethylene oxide sterilization (gaseous sterilization), exposure to ultraviolet rays or to gamma irradiation or sterilization by aseptic processing. These and other methods of sterilization are described in detail in Pharmaceutical Dosage Forms: Parenteral Medications (Eds. Avis, Lachman and Lieberman, Volumes 1-3).
Most of the conventional formulations for parenteral administration described above can be readily processed by one of the manufacturing processes mentioned above and the choice of an appropriate method for their sterilization is within the scope of understanding of a person of ordinary skill in the art of manufacture of parenteral dosage forms. Thus, solution formulations of bioactive agents which are stable to temperature can be readily autoclaved post-processing of the formulation and filling into the final container. This process known as "terminal sterilization" is generally used for ensuring sterility of large volume parenterals such as normal saline, dextrose saline and the like. For temperature labile bioactive agents the formulations have to necessarily be processed aseptically that is through filtration through sterilizing grade filters which have a nominal pore size of 0.22 μm. Similarly, such agents which are sensitive to temperature and also to water can also be filled into vials, ampoules or syringes and then lyophilized. Lyophilized products which are free from moisture are then reconstituted before administration providing a prolonged shelf-life. Other compositions can be sterilized by ethylene oxide or by irradiation. Each of these methods suffers from disadvantages such as residual ethylene oxide, degradation due to heat or irradiation and others.
It is especially difficult to manufacture sterile controlled release products for parenteral administration such as the microencapsulated products, in-situ forming implants and the in-situ microcarrier forming gelled polymeric dispersions. Of all of the controlled release products mentioned above, sterile processing of the in-situ microcarrier forming gelled polymeric dispersions poses the greatest challenge to the formulation scientist because of the complex nature of the delivery composition. These gelled polymeric dispersions are comprised of dispersions of organic solvent solutions of biocompatible polymers in a continuous oleaginous phase gelled and stabilized by emulsifiers chosen from sorbitan monostearate or monopalmitate. The organic solvents are preferably water-soluble though water-immiscible solvents can also be used. Upon coming in contact with an aqueous medium, the oily continuous phase gets emulsified and the polymers from the droplets precipitate through the mixing and extraction of water-soluble solvents from the droplets. The detailed composition and processes to make the compositions are described in US 20030049320 Al, AU 0222505 A5 and WO 02/49573 A3 to Bhagwatwar et al. and are all incorporated herein by reference.
Though different methods to prepare sterile compositions are described in the literature, the literature is silent with respect to sterile in-situ microcarrier forming gelled polymeric dispersions and processes to manufacture such compositions. Problems associated with the sterile processing of the in-situ microcarrier forming gelled polymeric dispersion compositions include: instability of the polymer to heat, moisture and gamma irradiation, difficulty of aseptic processing of drug-free or drug-containing polymer solutions of high concentrations of greater than 40 % /w of polymer and upto 50 % w/w of bioactive agent with respect to the polymer, and preparation of the sterile gelling agent bulk sorbitan monostearate or sorbitan monopalmitate.
The gelling agents of this invention as commercially available are not free from foreign particulate material and contain significant quantities of impurities which add color to the final product making it unacceptable for parenteral use. Further, the use of water for the processing of these gelling agents is not feasible because the gelling agents would degrade during autoclaving for example resulting in a loss of gelling capability. Also, presence of moisture in any of the materials, specially the gelling agent would result in the loss of physical stability of the gelled dispersions. A process to manufacture sterile in-situ microcarrier forming gelled polymeric dispersion compositions would be a tremendous improvement in the current state-of-the- art in the development of commercial products using these compositions.
There is thus a need for preparing a sterile bulk sorbitan monostearate or sorbitan monopalmitate gelling agent substantially free from moisture and foreign particulate matter thereby improving its utility value as a pharmaceutical entity.
There is a further need to provide a process for the manufacture of sterile in-situ microcarrier forming gelled polymeric dispersion compositions containing bioactive agents for their immediate or controlled release.
There is also a need to provide such sterile in-situ microcarrier forming gelled polymeric dispersion compositions for use in the treatment of various disease conditions in human beings and animals.
SUMMARY OF THE INVENTION
A novel method for the manufacture of sterile gelling agent for use in a suitable composition or delivery system for therapeutic administration is described. The method involves the use of aseptic processing alone or gamma-irradiation alone or a combination of aseptic processing and gamma irradiation to achieve a product of the desired attributes including sterility, freedom from foreign particulates, syringeability, particle formation upon coming in contact with aqueous media, potency of active, and physical stability.
The present inventors have surprisingly found that the manufacture of a sterile drug delivery system, with the desired characteristics is dependant on the successful preparation of a sterile gelling agent bulk which is free from foreign particulate matter and substantially free from moisture, while retaining its physicochemical characteristics like its capability to gel and physically stabilize the gelled polymeric dispersion composition if the sterile gelling agent be incorporated in a gelled polymeric drug delivery system.
The gelling agents of the invention include sorbitan monostearate or sorbitan monopalmitate which are known to be soluble in a variety of organic solvents (both volatile and non- volatile) at elevated temperatures followed by gelation of the solvents upon cooling. This principle has been used in the development of the in-situ microcarrier forming gelled polymeric dispersion compositions by Bhagwatwar et al. (US 20030049320 Al, AU 0222505 A5 and WO 02/49573 A3). The present inventors further have also astonishingly observed that certain volatile organic solvents such as ethanol, methanol and the like, not only act as good solvents for the gelling agents at elevated temperature but are readily removable through simple vacuum drying, with or without application of heat, without any change in the product characteristics. Further such solvents also ensure the sterility of the finished bulk. In addition, a majority of the solvent can be removed through the addition of a non- solvent such as for example water for injection. One other property of the use of such solvents includes that when excess solvent is added to the gelled bulk upon cooling, the sterile bulk gelling material precipitates out. Also, the residual solvent, if any remains after this rigorous processing, is non-toxic, as the solvents such as ethanol are acceptable for parenteral administration.
In another embodiment of the invention, a sterile gelling agent is prepared by subjecting a foreign particulate free gelling agent as processed above to gamma irradiation.
In another aspect of the invention a sterile polymer-drug solution is prepared by gamma irradiation of such a solution.
In yet another aspect of the invention, a in-situ microcarrier forming gelled polymeric dispersion composition prepared using the gelling agents treated as above are subjected to gamma irradiation to prepare a sterile product useful for human administration without any significant loss in potency or behavior of the gelled dispersion composition in physical stability, syringeabihty or particle formation upon coming in contact with aqueous media.
Another embodiment of the invention describes the administration of this sterile composition to an animal species.
These and other embodiments of the invention are described in greater detail in the further sections of this application.
DETAILED DESCRIPTION OF THE INVENTION
Preparation of a sterile gelling agent
The gelling agents of the invention include sorbitan monostearate and / or sorbitan monopalmitate. Both of these materials are available from a number of suppliers commercially for topical or oral use. Sterile material free from foreign particulates is not available and is difficult to produce. It is now possible to produce such sterile, foreign particulate free material through the use of aseptic precipitation and drying alone or in conjunction with gamma irradiation. It is essential that the process used for the preparation of a sterile bulk does not introduce any change in physicochemical properties of the gelling agent which will in turn cause a change in the gelling potential of the gelling agent.
The process to provide a foreign particulate free, sterile bulk gelling agent comprises the steps of: 1. Dissolution of the gelling agent(s) in volatile organic solvents, if required at an elevated temperature, followed by filtration of the solutions also at the elevated temperature and subsequent evaporation to obtain a dry product OR 2. Dissolution of the gelling agent(s) in water-miscible organic solvents at an elevated temperature followed by filtration of the solutions also at the elevated temperature, precipitation of the gelling agents from solution either through addition of a non-solvent or cooling the solution to a lower temperature to cause phase-separation, filtration to recover the wet bulk and subsequent evaporation to obtain a dry product AND 3. Subjecting the foreign particulate-free gelling agent obtained from steps 1 and 2 to sterilization by gamma irradiation
The gelling agents of the invention viz. sorbitan monostearate or sorbitan monopalmitate are soluble in a variety of organic solvents including volatile organic solvents such as methylene chloride, ethyl acetate, benzene, petroleum ether, carbon tetrachloride, methanol, acetonitrile, acetone, ethanol, tetrahydrofuran and other volatile solvents, at elevated temperatures. Non-volatile organic solvents in which the gelling agents are soluble include NN'-dimethylacetamide (DMA), dimethylsulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), triacetin, triethyl citrate, benzyl alcohol, propylene carbonate, decylmethylsulfoxide, dimethylformamide (DMF), glycofural, benzoyl benzoate, alkyl esters of aromatic acids, polyethylene glycols (PEG), propylene glycol and the like, also at elevated temperatures.
The solvents for the invention should be biocompatible and not pose toxicity issues. Such solvents may be completely water-miscible, partially water-miscible or completely water-immiscible. Water-im niscible organic solvents such as dichloromethane, chloroform, ether, benzene, hexane and the like though otherwise used in the preparation of pharmaceutical compositions are generally toxic and require exotic methods such as lyophilization and the like for removal. Also, there are very strict guidelines for the levels of such residual solvents allowable in pharmaceutical compositions, especially so for parenteral administration. Water-miscible organic solvents are preferred. More specifically, such water-miscible organic solvents are chosen from DMA, DMSO, NMP, triacetin, triethyl citrate, benzyl alcohol, propylene carbonate, decylmethylsulfoxide, DMF, glycofural, benzoyl benzoate, alkyl esters of aromatic acids, PEG, propylene glycol, isopropanol, methanol, acetonitrile, acetone, ethanol, tetrahydrofuran and the like. A specially preferred volatile water-miscible solvent is ethanol because of its proven antiseptic properties, its complete water-miscibility, its volatile nature, its biocompatibility and low toxicity potential, its solvating capability for the gelling agents of the invention at elevated temperatures and its known use in the pharmaceutical industry for parenteral administration of solution dosage forms. Preferred non-volatile water-miscible organic solvents include DMA, DMSO, DMF, NMP, PEG among others.
In one embodiment of the novel process of the invention, the sterile bulk gelling agent is prepared by dissolution in volatile water-miscible organic solvents specifically chosen from ethanol, methanol, acetonitrile, acetone, ethanol, tetrahydrofuran at a temperature above ambient, filtered through a sterilizing grade filter membrane at the elevated temperature and dried under vacuum at the elevated temperature.
In another aspect of this embodiment of the invention the solution of the gelling agent which has been filtered through a sterilizing grade filter membrane, is cooled to room temperature or lower to cause gelation of the solvent and the same solvent is added to the gel to cause precipitation of the gelling agent. This suspension is then filtered through a further sterilizing grade filter membrane and the wet mass which is substantially free from the organic solvent is then dried under vacuum at an elevated temperature. This procedure has the advantage of removal of a large percentage of the organic solvent from the gelled bulk which would otherwise be lost under vacuum. This solvent can then further be used in processing of a separate lot of the gelling agent. The term "substantially free" indicates that a large percentage of the organic solvent is removed when compared with the situation where all of the solvent is bound to the gelling agent in the form of a gel.
In a further embodiment of the invention, the solution of the gelling agent which has been filtered through sterilizing grade filter membranes at elevated temperatures is then added to a non-solvent to cause precipitation of the gelling agent. The non-solvent can be an organic solvent or can be water. The precipitated gelling agent is then treated further as in the earlier embodiment described above with the same advantages. In a further aspect of this embodiment, the water-miscible organic solvent is nonvolatile chosen from DMA, DMSO, NMP, triacetin, triethyl citrate, benzyl alcohol, decylmethylsulfoxide, DMF, glycofural, PEG, propylene glycol and the like. Upon precipitation from a non-solvent such as water, the gelling agent is subjected to drying to remove water. The residual organic solvent should be chosen advantageously to be the same as the one to be used in the final gelled polymeric dispersion.
In an additional embodiment of the invention, the sterile dried bulk gelling agent is subjected to sterilization by gamma irradiation. Surprisingly, the gelling agents are not degraded by this procedure. Other materials in the gelled polymeric dispersion can be processed by other techniques as described above and generally known in the art of preparation of sterile dosage forms.
The concentration of the gelling agent in the water-miscible solvent can be from 5 %w/w to 80 %w/w, preferably from about 10 %w/w to 70 %w/w and even more preferably from about 20 %w/w to 60 %w/w. The concentration of the gelling agent in the final solution will be dependent on the solvent chosen, the gelling agent solvent interactions, the processing temperature and of course the solubility of the gelling agent in the solvent. Of particular importance is the concentration of the gelling agent in the solvent, which allows filtration through a sterilizing grade membrane filter. The higher the concentration of the gelling agent in the solution the greater the yields and smaller the amounts of the expensive solvents that are used.
When a solvent / non-solvent type of precipitation is to be used, the ratio of the solvent to the non-solvent may be adjusted so that complete precipitation occurs to ensure maximum yields.
The temperature of preparation of the solution and also the processing will of course depend on the solvent to be used with a temperature below the boiling point of the solvent being preferred. Thus, for example, for a solvent such as ethanol a clear solution can be prepared at a temperature of 35-40 °C and higher at concentrations as high as 50 %w/w, which can be filtered through a sterilizing grade 0.22 μm filter at the same temperature. But, for a solvent such as DMA, a solution with the same concentration needs to be processed at a higher temperature because of the viscosity imparted by the gelling agent.
The gelling agents of the invention are known to gel the solvents of the invention at high concentrations. Each gelling agent-solvent system will have a different temperature range at which the gelation occurs which will also affect the processability of the solution.
The sterilizing grade filter can be any membrane, which has the capability to remove foreign particulates and also microorganisms to ensure sterility. Such filters usually have a pore size of 0.22 μm. Any membrane filter is acceptable for the practice of this invention as long as it can filter the solution and is compatible with the solvents of the invention. Such membranes include those made from nylon 66, cellulose acetate, cellulose nitrate, polytetrafluoroethylene (PTFE), silver membrane, gold membrane, polysulfone, polycarbonate and other known in the art and supplied by various manufacturers. The sterilizing grade filter could be preceded by a cleaning filter such as a 0.45 μm, 5 μm or 8 μm filter which can take up much of the burden from the sterilization filter. The choice of filters is within the scope of a person skilled in the art of development of pharmaceutical injectable dosage forms.
Any mode of filtration is acceptable as long as a sterile product is produced. Such methods include, vacuum filtration, filtration under positive pressure using compressed air or nitrogen and the like. Also, the use of cartridge filters or filter candles and the like are well within the scope of this description.
The drying of the sterile gelling agent bulk obtained after the above described processes can be conducted by any means known in the art including for example tray drying in an oven with or without the application of vacuum and with or without heating, lyophilization, simple vacuum drying and other methods known to a person skilled in the art of processing pharmaceutical dosage forms. Where heating is required it is preferable to heat at a temperature above the boiling point of the solvent to be evaporated to ensure complete removal of the organic solvent.
Further, for the preparation of a sterile in-situ microcarrier forming gelled polymeric dispersion composition, the preparation of sterile solvents, polymers, oil and bioactive agents can be as per known procedures in the art such as aseptic filtration of the solvents and oil, gamma irradiation of the polymer or aseptic filtration of the polymer solution in a volatile organic solvent followed by evaporation of the solvent and the like and are well known to persons skilled in the art of manufacture of parenteral controlled release dosage forms. The bioactive agents which can be incorporated into the sterile in-situ microcarrier foπriing gelled polymeric dispersion compositions can be chosen from peptide drugs, protein drugs, desensitizing agents, antigens, vaccines, anti-infectives, antibiotics, antimicrobials, antineoplastics, antitumor, antiallergenics, steroidal anti- inflammatory agents, analgesics, decongestants, miotics, anticholinergics, sympathomimetics, sedatives, hypnotics, antipsychotics,.psychic energizers, tranquilizers, androgenic steroids, estrogens, progestational agents, humoral agents, prostaglandins, analgesics, antispasmodics, antimalarials, antihistamines, cardioactive agents, non- steroidal anti-inflammatory agents, antiparkinsonian agents, antihypertensive agents, beta-adrenergic blocking agents, nutritional agents, antivirals, DNA fragments, nucleic acids, genetic material, oligonucleotides, radioisotopes, or combinations of these classes of compounds. To those skilled in the art, other drugs or biologically active agents that can be released in an aqueous environment can be utilized in the described delivery system. Also, various forms of the drugs or biologically active agents may be used. These include, without limitation, forms such as uncharged molecules, molecular complexes, salts, ethers, esters, amides, and other chemically modified forms of the biologically active agent which are biologically activated when injected into a body. In a further embodiment, the sterile bioactive agent may also be added to the oil phase as a suspension to enhance the loading of the bioactive agent in the delivery composition. Whatever the final composition that is arrived at the process allows a sterile composition to be prepared. Also, the further behavior of the delivery composition in forming a delivery system and the subsequent release of the bioactive agent is as described in US 20030049320 Al, AU 0222505 A5 and WO 02/49573 A3 to Bhagwatwar et al. and are all incorporated herein by reference.
The term "parenterally" as used herein is intended to include routes such as intramuscular, intravenous, subcutaneous, subdermal, intralesional, intratumoral, intracavitary, peritumoral, intraarticular, vaginal, intraperitoneal, intraabdominal, intrathecal, intraorgan and the like or on open wounds, fractures, ulcers, cancerous lesions and the like and is not to be construed as limiting on the scope of the invention. Thus, the composition can be used for the immediate or controlled release or both of bioactive agents or bioinactive agents wherever the use of a sterile composition is called for.
The following examples describe the invention in further detail and are not to be construed as limiting on the scope of the invention.
EXAMPLES
Examples 1-5 describe different methods for preparation of sterile sorbitan monostearate. The same methods can be applied to the preparation of other sterile gelling agents including sorbitan monopalmitate.
Comparative Example 1
Sorbitan monostearate (Sanyo, Japan) was subjected to sterilization by dry heat at a temperature of 180 °C for 2 hours. A dark brown colored mass was obtained. The material thus obtained though it would pass the test for sterility renders the final product unacceptable for pharmaceutical use because of the dark brown color it imparts.
Example 1 Preparation of sterile sorbitan monostearate by direct evaporation of the solvent from a solution in a volatile organic solvent
Sorbitan monostearate (Sanyo, Japan) was dissolved in ethanol (50 %w/v) by heating upto 60 - 65 °C in a water bath to form a clear solution. The hot solution was filtered through a 0.2 μm nylon 66 (Pall German) sterilizing grade membrane filter under vacuum using a specially fabricated jacketed stainless steel filtration assembly, which was also maintained, at the elevated temperature. The filtrate was dried in a vacuum oven at 40 °C and 760 mm vacuum for 48 hours. The dried material was crushed and stored in a sterile container free from moisture.
Example 2 Preparation of sterile sorbitan monostearate by dissolving in a hot volatile water- miscible solvent and precipitating by mixing with the same solvent which is cold
Sorbitan monostearate (Sanyo, Japan) was dissolved in ethanol (50 %w/v) by heating upto 60 - 65 °C in a water bath to form a clear solution. The hot solution was filtered through a 0.2 μm nylon 66 (Pall German) sterilizing grade membrane filter under vacuum using a specially fabricated jacketed stainless steel filtration assembly, which was also maintained, at the elevated temperature. The filtered solution was kept at 37 °C for 60 minutes and was then slowly added into cold, sterile, particulate free ethanol at 2 - 8 °C. The sorbitan monostearate precipitated as a fine powder at the bottom of the beaker. The precipitated sorbitan monostearate was collected and dried.
Example 3 Preparation of sterile sorbitan monostearate by dissolving in a volatile water- miscible organic solvent and precipitating from a non-solvent Sorbitan monostearate (Sanyo, Japan) was dissolved in ethanol (50 %w/v) by heating upto 60 — 65 °C in a water bath to form a clear solution. The hot solution was filtered through a 0.2 μm nylon 66 (Pall Gelman) sterilizing grade membrane filter under vacuum using a specially fabricated jacketed stainless steel filtration assembly that was also maintained at the elevated temperature. The sorbitan monostearate was precipitated by drop-wise addition of the filtered ethanolic solution into sterile water for injection. The supernatant was decanted off and the precipitated sorbitan monostearate was collected on a filter paper and dried under vacuum at an elevated temperature. The dried material was crushed and stored in a sterile container free from moisture.
Example 4 Preparation of sterile sorbitan monostearate by dissolving in a non-volatile water- miscible solvent and precipitating from a non-solvent
Sorbitan monostearate (Sanyo, Japan) was dissolved in DMA (Fluka) by heating upto 60 - 65 °C in a water bath to form a clear solution. This solution was slowly added into sterile water for injection to cause precipitation of sorbitan monostearate, which was collected and dried.
Example 5 Sterilization by gamma irradiation
Sorbitan monostearate prepared in Example 1 was exposed to gamma irradiation at a dose of 25 KGy using a 60Cobalt source at a contract irradiation laboratory. A dose of 25 KGy is accepted internationally to be sufficient to ensure sterility (British Pharmacopoeia). There was no change in appearance of the gelling agent.
These examples demonstrate that sterile sorbitan monostearate can be prepared by these techniques without any change in properties. The same techniques may be used to prepare sterile sorbitan monopalmitate. The further examples describe the use of the sterile sorbitan monostearate in the preparation of the gelled polymeric dispersions.

Claims

CLAIMS 1. We claim a sterile gelling agent for use in a drug delivery system, which is substantially free from foreign particulate material, substantially free from moisture and substantially free from impurities.
2. A sterile gelling agent of claim 1, which retains its physico-chemical properties.
3. A sterile gelling agent of claim 1, belonging to the class of fatty acids, fatty alcohols, their metallic salts and their analogues.
4. A sterile gelling agent of claim 3 wherein the agent is either sorbitan monostearate or sorbitan monopalmitate.
5. A process for preparing a sterile gelling agent as in claiml, comprising of a. dissolution of the gelling agent in an organic solvent, followed by aseptic filtration of the solution and subsequent evaporation of solvent to obtain a dry product OR b. dissolution of the gelling agent in a water-miscible organic solvent, followed by aseptic filtration of the solution, and subsequent precipitation or crystallization of the gelling agent from solution AND c. Optionally, sterilizing the product obtained by either a or b by gamma irradiation.
6. A process for preparing a sterile gelling agent as in claim 5, where the aseptic filtration of the gelling agent is carried out at a temperature at which the gelling agents gels the solvent without undergoing degradation.
7. A process for preparing a sterile gelling agent as in claim 6, where the aseptic filtration of the gelling agent is carried out at a temperature at which the integrity of the filter membrane is not lost during aseptic filtration.
8. A process for preparing a sterile gelling agent as in claim 6, where the temperature used is below the boiling point of the organic solvent.
9. A process of claim 5 wherein an organic solvent is a volatile and water-miscible alkanol.
10. A process of claim 5 wherein the organic solvent is preferably ethyl alcohol.
11. A process of claim 5 wherein the organic solvent is either volatile or non volatile.
12. A process of claim 5 wherein the organic solvent is either water miscible or water immiscible.
13. A process of claim 5 wherein the organic solvent is volatile and is water miscible and is chosen from methylene chloride, ethyl acetate, benzene, petroleum ether, carbon tetrachloride or is non- volatile and is water miscible and is chosen from methanol, acetonitrile, acetone, ethanol, tetrahydrofuran, isopropanol.
14. The process of claim 5 wherein the organic solvent for the gelling agent is nonvolatile and is water miscible and is chosen from N, N-dimethylacetamide, dimethylsulfoxide, N-methyl-2-pyrrolidone, triacetin, triethyl citrate, benzyl alcohol, propylene carbonate, decylmethylsulfoxide, dimethylformamide, glycofural, benzoyl benzoate, alkyl esters of aromatic acids, polyethylene glycols, propylene glycol, sorbitol and glycerol.
15. A process as in claim 5 wherein the concentration of the gelling agent in the solution for aseptic processing is from about 5% to about 80%w/w.
16. A process as in claim 5, wherein the filter used is of sterilizing grade.
17. A sterile gelling agent of claim 1 optionally sterilized by gamma radiation or obtained by an aseptic process.
EP03748442A 2003-10-14 2003-10-14 Sterile gelling agents Withdrawn EP1558215A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2003/004509 WO2005037252A1 (en) 2003-10-14 2003-10-14 Sterile gelling agents

Publications (2)

Publication Number Publication Date
EP1558215A1 true EP1558215A1 (en) 2005-08-03
EP1558215A4 EP1558215A4 (en) 2007-09-12

Family

ID=34452204

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03748442A Withdrawn EP1558215A4 (en) 2003-10-14 2003-10-14 Sterile gelling agents

Country Status (3)

Country Link
EP (1) EP1558215A4 (en)
AU (1) AU2003267747A1 (en)
WO (1) WO2005037252A1 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2209671A (en) * 1987-09-15 1989-05-24 Sandoz Ltd Water soluble monoesters as solubilisers
EP0712631A2 (en) * 1994-11-21 1996-05-22 Biogal Gyogyszergyar Rt. Cyclosporin containing multiple emulsions
WO1998023226A1 (en) * 1996-11-26 1998-06-04 The Regents Of The University Of California Biological tissue transplant coated with stabilized multilayer alginate coating suitable for transplantation and method for preparation thereof
WO2000044808A1 (en) * 1999-02-01 2000-08-03 Hubbell Jeffrey A Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
WO2000074650A2 (en) * 1999-06-04 2000-12-14 Alza Corporation Implantable gel compositions and method of manufacture
US6165225A (en) * 1995-10-13 2000-12-26 Islet Sheet Medical Llc Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change, processes for their manufacture, and methods for their use
WO2002000193A2 (en) * 2000-06-23 2002-01-03 Battelle Memorial Institute Multiple stimulus reversible hydrogels

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133863A (en) * 1961-03-10 1964-05-19 Strong Cobb Arner Inc Sustained release therapeutic tablet compositions comprising organic solvent-gelled gums
US4937081A (en) * 1988-01-14 1990-06-26 Daicel Chemical Industries Ltd. Process for producing porous, spherical particles

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2209671A (en) * 1987-09-15 1989-05-24 Sandoz Ltd Water soluble monoesters as solubilisers
EP0712631A2 (en) * 1994-11-21 1996-05-22 Biogal Gyogyszergyar Rt. Cyclosporin containing multiple emulsions
US6165225A (en) * 1995-10-13 2000-12-26 Islet Sheet Medical Llc Retrievable bioartificial implants having dimensions allowing rapid diffusion of oxygen and rapid biological response to physiological change, processes for their manufacture, and methods for their use
WO1998023226A1 (en) * 1996-11-26 1998-06-04 The Regents Of The University Of California Biological tissue transplant coated with stabilized multilayer alginate coating suitable for transplantation and method for preparation thereof
WO2000044808A1 (en) * 1999-02-01 2000-08-03 Hubbell Jeffrey A Biomaterials formed by nucleophilic addition reaction to conjugated unsaturated groups
WO2000074650A2 (en) * 1999-06-04 2000-12-14 Alza Corporation Implantable gel compositions and method of manufacture
WO2002000193A2 (en) * 2000-06-23 2002-01-03 Battelle Memorial Institute Multiple stimulus reversible hydrogels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2005037252A1 *

Also Published As

Publication number Publication date
WO2005037252A1 (en) 2005-04-28
EP1558215A4 (en) 2007-09-12
AU2003267747A1 (en) 2005-05-05

Similar Documents

Publication Publication Date Title
Kempe et al. In situ forming implants—an attractive formulation principle for parenteral depot formulations
US9278139B2 (en) Sterilization of biodegradable hydrogels
US6916788B2 (en) Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof
ES2283394T3 (en) IMPLEMENTATION KIT CONTAINING A SUPPORT PHASE AND A SOLVENT.
RU2409348C2 (en) Medicinal agents with controlled release based on block-copolymers
JPH0834747A (en) Injectable drug delivery preparation based on collagen and its use
US20080063716A1 (en) Method of formation of shape-retentive aggregates of gel particles and their uses
US20060286130A1 (en) Sterile gelling agents
ES2569556T3 (en) Dehydrated hydrogel inclusion complex of a bioactive agent with fluid medication delivery system
EP1558215A1 (en) Sterile gelling agents
US20070003626A1 (en) Sterile in-situ microcarrier forming gelled polymeric dispersions and processes to manufacture the same
CN116370707A (en) Injection filler and preparation method thereof
EP2796127A1 (en) Crosslinked gelatin support for controlled release of physiologically active substance
Chakraborty et al. Silk fibroin: A smart biomaterial for long term and targeted nanotherapeutics
Nun Improving Skin Wound Healing Using Functional Electrospun Wound Dressings and 3D Printed Tissue Engineering Constructs
Khwaza et al. Ruwizhi Ngonidzashe, Opeoluwa O. Oyedeji and Blessing A. Aderibigbe Department of Chemistry, University of Fort Hare, Alice Campus, Eastern Cape, South Africa
Baskakova Perspective materials for drug delivery in the ophthalmic dosage form: a short review of polymers for electrospinning
CN118078820A (en) Combretastatin A4/BLZ 945/macromolecule nano-drug freeze-dried powder, preparation method, nano-drug preparation and application thereof
Alexandra Perspective materials for drug delivery in the ophthalmic dosage form: a short review of polymers for electrospinning
Bhalerao et al. A Review on Atrigel: a novel drug delivery system forming implants
Baskakova Research Results in Biomedicine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050520

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: YEOLA, BHUSHAN SUBHASH

Owner name: KADAM, CHANDRSHAKHAR SHIVAJIRAO

Owner name: MATHAKIYA, ISMAIL ALIBHAI

Owner name: BAPAT, VARADA RAMESH

Owner name: SHARMA, PRADEEP

Owner name: PAITHANKAR, MAHESH BALKRISHNA

Owner name: BHAGWATWAR, PRABHAKAR HARSHAL

Owner name: WOCKHARDT LIMITED

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20070814

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/26 20060101ALI20070808BHEP

Ipc: A61K 9/00 20060101ALI20070808BHEP

Ipc: A61K 9/14 20060101AFI20050504BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071113